These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 24806995)

  • 1. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.
    Pellicano F; Scott MT; Helgason GV; Hopcroft LE; Allan EK; Aspinall-O'Dea M; Copland M; Pierce A; Huntly BJ; Whetton AD; Holyoake TL
    Stem Cells; 2014 Sep; 32(9):2324-37. PubMed ID: 24806995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.
    Naka K; Hoshii T; Muraguchi T; Tadokoro Y; Ooshio T; Kondo Y; Nakao S; Motoyama N; Hirao A
    Nature; 2010 Feb; 463(7281):676-80. PubMed ID: 20130650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells.
    Pellicano F; Cilloni D; Helgason GV; Messa F; Panuzzo C; Arruga F; Bracco E; Allan E; Huntly BJ; Holyoake TL; Saglio G
    Blood; 2009 Dec; ():. PubMed ID: 19965658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
    Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
    Joha S; Nugues AL; Hétuin D; Berthon C; Dezitter X; Dauphin V; Mahon FX; Roche-Lestienne C; Preudhomme C; Quesnel B; Idziorek T
    Oncogene; 2012 Mar; 31(11):1419-30. PubMed ID: 21804606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
    Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL
    Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
    Tan Z; Peng A; Xu J; Ouyang M
    BMC Anesthesiol; 2017 Sep; 17(1):132. PubMed ID: 28962554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.
    Moreno-Lorenzana D; Avilés-Vazquez S; Sandoval Esquivel MA; Alvarado-Moreno A; Ortiz-Navarrete V; Torres-Martínez H; Ayala-Sánchez M; Mayani H; Chavez-Gonzalez A
    Cell Cycle; 2016 May; 15(9):1276-87. PubMed ID: 26985855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H; Chen M; Rothe K; Lorenzi MV; Woolfson A; Jiang X
    Oncotarget; 2014 Sep; 5(18):8637-50. PubMed ID: 25226617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
    O'Hare T; Eide CA; Agarwal A; Adrian LT; Zabriskie MS; Mackenzie RJ; Latocha DH; Johnson KJ; You H; Luo J; Riddle SM; Marks BD; Vogel KW; Koop DR; Apgar J; Tyner JW; Deininger MW; Druker BJ
    Cancer Res; 2013 Jun; 73(11):3356-70. PubMed ID: 23576564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
    Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
    Liu Z; Li Y; Lv C; Wang L; Song H
    Biochem Biophys Res Commun; 2016 Sep; 478(2):893-9. PubMed ID: 27520370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
    Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
    Zhou Z; Liu T; Zhang J
    Biochem Biophys Res Commun; 2019 Dec; 520(3):560-565. PubMed ID: 31615652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
    Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
    Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
    Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
    BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.